Another study showed a significant increase in the expression of cytokine (CCL5, CXCL10, and IFN-β) mRNA and the survival of animals by an ATR inhibitor (BAY1895344) plus anti-PD-L1 therapy, compared with BAY1895344 or anti-PD-L1 therapy alone in prostate cancer mouse models [168]. This evidence concerns the gene CD274 and prostate carcinoma.